Peter M. Gordon

2.0k total citations
36 papers, 1.1k citations indexed

About

Peter M. Gordon is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Peter M. Gordon has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Immunology and 8 papers in Oncology. Recurrent topics in Peter M. Gordon's work include Acute Lymphoblastic Leukemia research (8 papers), RNA and protein synthesis mechanisms (5 papers) and RNA modifications and cancer (5 papers). Peter M. Gordon is often cited by papers focused on Acute Lymphoblastic Leukemia research (8 papers), RNA and protein synthesis mechanisms (5 papers) and RNA modifications and cancer (5 papers). Peter M. Gordon collaborates with scholars based in United States, United Kingdom and France. Peter M. Gordon's co-authors include Joseph A. Piccirilli, Erik J. Sontheimer, Heather M. Wilson, Robert N. Barker, Claire S. Whyte, Andrew J. Rees, Robert Fong, David E. Fisher, Tony Ng and Nathan Gossai and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Blood.

In The Last Decade

Peter M. Gordon

33 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter M. Gordon United States 18 585 303 161 100 87 36 1.1k
Guglielmo Rosignoli United Kingdom 14 418 0.7× 430 1.4× 106 0.7× 103 1.0× 101 1.2× 21 886
Elena Ossipova Sweden 13 331 0.6× 250 0.8× 125 0.8× 76 0.8× 93 1.1× 30 1.1k
Yoshiko Matsumoto Japan 16 382 0.7× 231 0.8× 194 1.2× 166 1.7× 66 0.8× 39 897
Amy M. Becker United States 15 296 0.5× 488 1.6× 110 0.7× 85 0.8× 52 0.6× 22 904
Steven M. Chirieleison United States 12 831 1.4× 353 1.2× 200 1.2× 48 0.5× 87 1.0× 16 1.2k
Rita Bisogni Italy 14 502 0.9× 239 0.8× 192 1.2× 84 0.8× 44 0.5× 25 868
Wanxia Li Tsai United States 11 329 0.6× 390 1.3× 132 0.8× 84 0.8× 43 0.5× 22 796
Satoshi Yamaji Japan 17 534 0.9× 160 0.5× 143 0.9× 94 0.9× 56 0.6× 41 1.1k
Hendra Setiadi United States 17 374 0.6× 383 1.3× 176 1.1× 217 2.2× 53 0.6× 31 1.1k
Gabriele Zuchtriegel Germany 15 246 0.4× 394 1.3× 151 0.9× 129 1.3× 84 1.0× 19 877

Countries citing papers authored by Peter M. Gordon

Since Specialization
Citations

This map shows the geographic impact of Peter M. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Gordon more than expected).

Fields of papers citing papers by Peter M. Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Gordon. The network helps show where Peter M. Gordon may publish in the future.

Co-authorship network of co-authors of Peter M. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Gordon. A scholar is included among the top collaborators of Peter M. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Gordon. Peter M. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gordon, Peter M., Robin Williams, Kimyeong Lee, et al.. (2025). An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia. PubMed. 2(3). 100120–100120.
2.
Wang, Xiaohong, et al.. (2024). Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia. Frontiers in Oncology. 14. 1440650–1440650.
3.
Koppenhafer, Stacia L., et al.. (2022). Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. Oncogene. 41(20). 2873–2884. 4 indexed citations
4.
Opzoomer, James W., Joanne E. Anstee, Isaac Dean, et al.. (2021). Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Science Advances. 7(45). eabg9518–eabg9518. 56 indexed citations
5.
Ebadi, Maryam, et al.. (2021). CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance. Scientific Reports. 11(1). 24374–24374. 6 indexed citations
6.
Basile, Patrick, et al.. (2020). The meninges enhance leukaemia survival in cerebral spinal fluid. British Journal of Haematology. 189(3). 513–517. 4 indexed citations
7.
Goss, Kelli L., Stacia L. Koppenhafer, William W. Terry, et al.. (2020). The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene. 40(3). 564–577. 16 indexed citations
8.
Ebadi, Maryam, et al.. (2019). Ruxolitinib combined with chemotherapy can eradicate chemorefractory central nervous system acute lymphoblastic leukaemia. British Journal of Haematology. 187(1). e24–e27. 6 indexed citations
9.
Ebadi, Maryam, et al.. (2019). Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance. Haematologica. 105(8). 2130–2140. 19 indexed citations
10.
Widen, John C., et al.. (2018). SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. Bioconjugate Chemistry. 29(4). 1111–1118. 16 indexed citations
11.
Muliaditan, Tamara, Jonathan Caron, James W. Opzoomer, et al.. (2018). Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis. Nature Communications. 9(1). 2951–2951. 90 indexed citations
12.
Gordon, Peter M., et al.. (2014). The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses. Immunobiology. 220(1). 10–19. 65 indexed citations
13.
Gordon, Peter M. & David E. Fisher. (2010). Role for the Proapoptotic Factor BIM in Mediating Imatinib-induced Apoptosis in a c-KIT-dependent Gastrointestinal Stromal Tumor Cell Line. Journal of Biological Chemistry. 285(19). 14109–14114. 33 indexed citations
14.
Gordon, Peter M., Robert Fong, & Joseph A. Piccirilli. (2007). A Second Divalent Metal Ion in the Group II Intron Reaction Center. Chemistry & Biology. 14(6). 607–612. 52 indexed citations
15.
Pellagatti, Andrea, Fiona Watkins, Cordelia F. Langford, et al.. (2004). Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. British Journal of Haematology. 125(5). 576–583. 60 indexed citations
16.
Gordon, Peter M., Robert Fong, Shirshendu K. Deb, et al.. (2004). New Strategies for Exploring RNA's 2′-OH Expose the Importance of Solvent during Group II Intron Catalysis. Chemistry & Biology. 11(2). 237–246. 30 indexed citations
17.
Gordon, Peter M. & Joseph A. Piccirilli. (2001). Metal ion coordination by the AGC triad in domain 5 contributes to group II intron catalysis.. Nature Structural Biology. 8(10). 893–898. 87 indexed citations
18.
Gordon, Peter M., Erik J. Sontheimer, & Joseph A. Piccirilli. (2000). Metal ion catalysis during the exon-ligation step of nuclear pre-mRNA splicing: Extending the parallels between the spliceosome and group II introns. RNA. 6(2). 199–205. 95 indexed citations
19.
Gordon, Peter M., et al.. (1994). Cutaneous cryptococcal infection without immunodeficiency. Clinical and Experimental Dermatology. 19(2). 181–184. 12 indexed citations
20.
Gordon, Peter M.. (1955). Complement Activity in the Eviscerate Rat.. Experimental Biology and Medicine. 89(4). 607–608. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guglielmo Rosignoli Breakdown of academic impact, for papers by Elena Ossipova Breakdown of academic impact, for papers by Yoshiko Matsumoto Breakdown of academic impact, for papers by Amy M. Becker Breakdown of academic impact, for papers by Steven M. Chirieleison Breakdown of academic impact, for papers by Rita Bisogni Breakdown of academic impact, for papers by Wanxia Li Tsai Breakdown of academic impact, for papers by Satoshi Yamaji Breakdown of academic impact, for papers by Hendra Setiadi Breakdown of academic impact, for papers by Gabriele Zuchtriegel
Rankless by CCL
2026